Sustained health-related quality of life in patients with severe heterogenous emphysema treated with spiration valve system at 24-month follow-up (EMPROVE)
G. Criner (Philadelphia, United States), A. Delage (Sherbrooke, Canada), K. Voelker (Sarasota, Florida, United States), S. Martel (Quebec, Canada), E. The Emprove Trial Investigator Group (Philadelphia, United States)
Source: International Congress 2022 – ALERT 4: Asthma and interventional pulmonology
Session: ALERT 4: Asthma and interventional pulmonology
Session type: Clinical trials session
Number: 4449
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Criner (Philadelphia, United States), A. Delage (Sherbrooke, Canada), K. Voelker (Sarasota, Florida, United States), S. Martel (Quebec, Canada), E. The Emprove Trial Investigator Group (Philadelphia, United States). Sustained health-related quality of life in patients with severe heterogenous emphysema treated with spiration valve system at 24-month follow-up (EMPROVE). 4449
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|